UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): February 27,
2007
NEOSTEM,
INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
0-10909
|
22-2343568
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
No.)
|
|
420
Lexington Avenue, Suite 450
New
York, New York
|
10170
|
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
|
Registrant’s
telephone number, including area code:
(212) 584-4814
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Item
7.01. Regulation FD
Disclosure.
NeoStem,
Inc. (the “Company”), is furnishing presentation materials, included as Exhibit
99.1 to this current report and incorporated into this item by reference,
which
will be used by the Company at a healthcare conference on February 27,
2007.
Item
9.01. Financial Statements and
Exhibits.
(d)
Exhibits.
Exhibit
99.1 Presentation
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereto
duly authorized.
|
Dated: February 27,
2007
|
||
|
NEOSTEM,
INC.
|
||
| By: |
/s/
Catherine M. Vaczy
|
|
|
Catherine
M. Vaczy
|
||
|
Vice
President and General
Counsel
|
||
NeoStem™
Business Initiatives 2007 Robin Smith, MD, MBA CEO and Chairman of the Board
Molecular Medicine - Tri Conference February 27, 2007 - San Francisco,
California
2
FORWARD LOOKING STATEMENTS This presentation contains “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause the actual results, performance
or achievements of NeoStem, or industry results, to be materially different
from
any future results, performance or achievements expressed or implied by such
forward-looking statements. When used in this presentation, statements that
are
not statements of current or historical fact may be deemed to be forward-looking
statements. Additionally, statements concerning: the Company’s ability to
develop the adult stem cell business, the future of regenerative medicine
and
the role of adult stem cells in that future, the future use of adult stem
cells
as a treatment option and the potential revenue growth of such business are
forward-looking statements. The Company’s ability to enter the adult stem cell
arena and future operating results are dependent upon many factors including
but
not limited to (i) the Company’s ability to obtain sufficient capital or a
strategic business arrangement to fund its expansion plans; (ii) the Company’s
ability to build the management and human resources and infrastructure necessary
to support the growth of its business and obtain appropriate state and other
licenses; (iii) competitive factors and developments beyond the Company's
control; (iv) scientific and medical developments beyond the Company’s control
including development in the potential therapeutic use of adult stem cells
and
(v) other risk factors discussed in the Company’s periodic filings with the
Securities and Exchange Commission which are available for review at www.sec.gov
under “Search for Company Filings.” You are cautioned not to place undue
reliance on these forward looking statements, which speak only as of the
date
hereof.
3 15 Minute Agenda Collections performed at company owned centers Processing and Storage (recurring revenue) Neostem today Vision for the future Questions
4
Company Overview NeoStem: Pioneer the pre-disease collection, processing and storage of stem cells from adult donors that can be accessed for his or her own use for future medical treatment Provides a process that is safe and non-invasive Uses proprietary technology for the mobilization, processing and multiple use storage With re-infusion does not have the risk of rejection or graft vs. host disease Is well positioned to be the leading provider of autologous adult stem cells for therapeutic use in regenerative medicine Not caught in political policy, debate or religious controversy Publicly traded company: NEOI.OB
5 Business Model NeoStem generates revenue from: Collections Storage (recurring revenue) Utilization Fee (when cells are used)
6
Market for NeoStem?s Services By 2010, it is estimated that 39% of the U.S. population (over 110 mm people) will be 45 years of age or older. Anticipated rapid increase in age associated diseases. Millions of Americans suffer from diseases that can be treated with their own stem cells. ?Bio-Insurance? - any adult who can afford it should consider banking their own stem cells for future use to treat disease.
7
Stem Cell Therapeutics for Targeted Diseases *Miscellaneous Sources 53,000,000
Potential NeoStem Clients Total 204,999 diagnosed new cases per year Breast
Cancer 10 million Osteoporosis 1.5 million Parkinson 200,000 Sickle Cell
Anemia
20.8 million Diabetes 253,000 Spinal Cord Injury 4.7 million stroke survivors
(500,000 new cases per year) Stroke 2.1 million Rheumatoid Arthritis 500,000
Crohn’s Disease 1.4 million Lupus 388,571 Multiple Sclerosis 5 million (550,000
new cases per year) Congestive Heart Failure 6 million Coronary Artery Disease
192,155 Lymphoma & Multiple Myeloma 208,080 Leukemia Prevalence* Disease
8
Adult Stem Cell Clinical Trials •196 Adult Autologous Stem Cell Clinical Trials
•667 Adult Stem Cell Clinical Trials
9
Adult Stem Cell Therapy in the News Dr. Burt treating Lupus with adult stems
cells at Northwestern Hospital.
10
Company Chronology Signed second collection agreement with Dr. Ivan Goldsmith
in
Las Vegas, NV Feb ’07 Raised $2.5 million dollars through the sale of common
stock and detachable warrants Jan-Feb ’07 Signed strategic alliance with UTEK to
identify licensing opportunities and expand IP portfolio Jan ’07 Neostem signs 5
year agreement with Hemacare for collection services Dec ’06 Started Collecting
Adult Stem Cells Nov ’06 Registration Statement Declared Effective Nov ’06
Signed first collection center agreement with Dr. Rothenberg –Encinitas, CA Sept
’06 Changed name from Phase III Medical to NeoStem, Inc.- Effected a 1:10
Reverse Stock Split Aug ’06 Raised $3.75 million dollars through the sale of
common stock and detachable warrants June-Aug ’06 Phase III Medical acquired
NeoStem Jan ’06 Phase III Medical – decided to exit legacy businesses and focus
on stem cells Pre 2006
2006
11 “Go-to-Market” Strategy Drive General Awareness – Direct to Consumers • The
benefits of storing and using Adult Stem Cells is very attractive to the
media •
Market as “Bio-Insurance” • High net worth & educated consumer • Family
history of certain diseases • Families that have stored umbilical cord blood
(“Family Plan”) Collaborations with High Profile Medical Academic Institutions •
Involved with cutting edge research (research grants) • Provide collection
services for ongoing clinical trials • Potential source of additional collection
centers Partner with Physicians • Wellness physicians • Establish relationships
with physicians in disparate specialties, such as cardiology, oncology and
rheumatology.
12
Scientific Advisory Board Wayne A. Marasco, M.D., Ph.D. Chairman of Scientific
Advisory Board. Associate Professor- Department of Cancer and Immunology
&
AIDS at the Dana- Farber Cancer Institute and Associate Professor of Medicine
at
Harvard Medical School. He will take the lead in expanding the Company’s
academic relationships and research collaborations.
13
Scientific Advisory Board Douglas W. Losordo, MD For many years a Professor
of
Medicine at Tufts University School of Medicine and Chief of Cardiovascular
Research at St. Elizabeth’s Medical Center in Boston, Dr. Lorsordo was recently
appointed Professor of Medicine at Northwestern University and Director of
the
Feinberg Cardiovascular Research Institute and Program in Cardiovascular
Regenerative Medicine. A Fellow or Member of many national professional
organizations, he currently serves on committees of the American College
of
Cardiology, the American Diabetes Association and the American Society of
Gene
Therapy where he chairs the Cardiovascular Gene Therapy Committee. Dr. Losordo
serves as Principal Investigator in many grant research projects and has
published widely, contributing to more than 300 professional articles, abstracts
and book chapters in recent years. He also serves on the Editorial Boards
of
numerous medical specialty journals including Stem Cells, Vascular Medicine
and
Circulation Research.
14
Scientific Advisory Board Stephen D. Nimer, MD Dr. Nimer is Professor of
Medicine and Professor of Pharmacology at Weill Medical College of Cornell
University. He also serves as Chief of Hematology Service and Head of the
Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center
in
New York City. Dr. Nimer is a member of many national professional
organizations, including the American Society of Hematology, the American
Society of Clinical Oncology, and the International Society for Stem Cell
Research. He serves as a Reviewer for major medical journals, including the
New
England Journal of Medicine and the Journal of the American Medical Association
(JAMA) among many others. He serves on numerous national and international
Grant
Review Committees and is a prominent invited speaker at conferences on his
areas
of expertise. He has authored or co-authored nearly 200 peerreviewed papers,
reviews, editorials and textbook chapters, primarily focused on issues
concerning hematology and oncology.
15
Advisory Board Ron Rothenberg MD, FACEP Dr. Rothenberg is a Fellow of the
American College of Emergency Physicians (FACEP) and is the founder of the
California HealthSpan Institute in Encinitas, California. He was the 10th
M.D.
in the world to become fully board certified by the American Board of Anti-Aging
Medicine. A graduate of Columbia University, College of Physicians and Surgeons,
and a specialist in Emergency Medicine at Los Angeles County-USC Medical
Center,
he has served as Clinical Professor of Preventive and Family Medicine at
the
UCSD School of Medicine Clinical Facility. He is currently Attending Physician
at Scripps Memorial Hospital in Encinitas.
16
Additional Company Initiatives • Develop strategic initiatives with – Cord blood
companies – Tissue banks – Pharmaceutical companies • Academic institutions for
licensing opportunities and build out of collection centers • Partnerships with
executive health programs, medical spas and first responder groups • Expand
intellectual property portfolio within the stem cell arena • Grant applications
to National Institutes of Health and others • Formation of Adult Stem Cell
Foundation
17
Summary • NeoStem has the first to market advantage in the collection and
storage of stem cells extracted from adults. • NeoStem represents a high growth
opportunity in a large growing market. • NeoStem is well positioned with
industry leaders and academic institutions. • NeoStem has an attractive
valuation compared to other stem cell related companies and is not capital
intensive. There are 26,551,213 shares of common stock outstanding at February
23, 2007.
18 Questions